Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, No,15 Changle West Road, Xi'an, China.
Radiat Oncol. 2012 Jan 10;7:2. doi: 10.1186/1748-717X-7-2.
To evaluate the clinical outcomes and patterns of failure in patients with nasopharyngeal carcinoma (NPC) treated with intensity modulated radiotherapy (IMRT) in Northwest China.
From January 2006 to December 2009, 138 NPC patients were treated at Xijing Hospital. Of them, 25 cases with stage I-II received IMRT only, 113 cases with stage III-IVb received IMRT plus accomplished platinum-based chemotherapy. The IMRT prescribed dose was PTV 68-74 Gy to gross disease in nasopharynx and 66-72 Gy to positive lymph nodes in 30-33 fractions, and high risk and low risk region PTV was 60-63 Gy and 50.456 Gy in 3033 and 28 fractions respectively. Plasma Epstein Barr virus (EBV) DNA load was measured before treatment. The clinical toxicities, outcomes and patterns of failure were observed.
The median follow up time was 23 months (range 2 to 53 months). EBV infection positive was only 15.9%. Overall disease failure developed in 36 patients, 99% belonged to stage III/IV disease. Among these, there were 26 distant metastases, 6 local recurrence, and 4 regional recurrence. The 3-year local control rate(LCR), distant metastasis-free survival (MFS), disease-free survival (DFS) and the overall survival (OS) was 93.9%, 79.5%, 70% and 83.1% respectively. Multivariate analyses revealed that age and anemia pre-radiotherapy were independent predictors for OS.
IMRT with or without chemotherapy can improve the long term survival of NPC patients in Northwest China. Distant metastasis becomes the main cause of treatment failure. Age and anemia before radiotherapy were the main prognosis factors of NPC patients.
评估中国西北地区接受调强放疗(IMRT)治疗的鼻咽癌(NPC)患者的临床结果和失败模式。
从 2006 年 1 月至 2009 年 12 月,138 例 NPC 患者在西京医院接受治疗。其中,25 例 I 期-II 期患者仅接受 IMRT 治疗,113 例 III-IVb 期患者接受 IMRT 加完成铂类化疗。IMRT 规定的剂量为 PTV 68-74Gy 用于鼻咽部大体疾病,PTV 66-72Gy 用于阳性淋巴结,分 30-33 次。高危和低危区域 PTV 分别为 60-63Gy 和 50.456Gy,分 3033 和 28 次。在治疗前测量血浆 Epstein Barr 病毒(EBV)DNA 载量。观察临床毒性、结果和失败模式。
中位随访时间为 23 个月(范围 2-53 个月)。EBV 感染阳性仅为 15.9%。36 例患者出现总体疾病失败,99%属于 III/IV 期疾病。其中,26 例远处转移,6 例局部复发,4 例区域复发。3 年局部控制率(LCR)、无远处转移生存(MFS)、无疾病生存(DFS)和总生存(OS)分别为 93.9%、79.5%、70%和 83.1%。多因素分析显示,年龄和放疗前贫血是 OS 的独立预测因素。
IMRT 联合或不联合化疗可提高中国西北地区 NPC 患者的长期生存率。远处转移成为治疗失败的主要原因。放疗前的年龄和贫血是 NPC 患者的主要预后因素。